logo

For the Inventor, By the Inventor

New York, NY, United States of America

Antecip Bioventures Ii LLC

Calculating rank
USPTO Granted Patents = 269



Forward Citations = 17,046

Loading Chart...
Loading Chart...

5 inventors (with patents filed for the assignee):

goldMedal Herriot Tabuteau (269 out of 426 patents)

silverMedal Graeme Jones (7 out of 7 patents)

bronzeMedal Jaro I Karppinen (4 out of 4 patents)

4.  Eric K H Dinkla (2 out of 2 patents)

5.  Herriot Tabuteu (1 out of 1 patent)

6.  Eric K Dinkla (0 patent)

7.  Graeme Jones (0 patent)


Core Competencies:
Bupropion
Dextromethorphan
Depression
Neurological Conditions
Psychiatric Conditions
Drug Modulator
Combination Therapy
Oral Administration
Dosage Forms
Suicide Risk Reduction
Metabolizers Treatment

269 patents:

1. 12766139 - Bupropion as a modulator of drug activity (2026-10-20),
2. 12740949 - Treatment of agitation associated with Alzheimer's disease with a combination of bupropion and dextromethorphan (2026-09-22),
3. 12678506 - Pharmaceutical compositions comprising bupropion and cysteine (2026-07-14),
4. 12661408 - Pharmaceutical compositions comprising bupropion and cysteine (2026-06-23),
5. 12653795 - Bupropion as a modulator of drug activity (2026-06-16),
6. 12599576 - Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan (2026-04-14),
7. 12576078 - Compounds and combinations thereof for treating neurological and psychiatric conditions (2026-03-17),
8. 12569479 - Bupropion as a modulator of drug activity (2026-03-10),
9. 12564587 - Bupropion dosage forms with reduced food and alcohol dosing effects (2026-03-03),
10. 12478622 - Bupropion dosage forms with reduced food and alcohol dosing effects (2025-11-25),
11. 12472174 - Bupropion dosage forms with reduced food and alcohol dosing effects (2025-11-18),
12. 12472156 - Compounds and combinations thereof for treating neurological and psychiatric conditions (2025-11-18),
13. 12472155 - Compounds and combinations thereof for treating neurological and psychiatric conditions (2025-11-18),
14. 12447138 - Bupropion as a modulator of drug activity (2025-10-21),
15. 12433884 - Compounds and combinations thereof for treating neurological and psychiatric conditions (2025-10-07),
Company Overview
Antecip Bioventures II LLC is a New York-based company focused on advancing psychiatric treatment through innovative drug development. The organization specializes in therapies targeting neurological and psychiatric conditions, with a particular emphasis on compounds such as bupropion and dextromethorphan. By exploring combination therapies and drug modulation techniques, Antecip aims to enhance treatment efficacy and improve patient outcomes in the realm of mental health. Their commitment to oral administration methods underscores their dedication to patient-friendly solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

269 Patents

#58 in New York, NY

#113 in New York

#1,616 in US

#3,267 in the World

New York, NY (US)
New York, NY, United States of America

Antecip Bioventures Ii LLC

Forward Citations = 17,046

5 inventors:

goldMedal Herriot Tabuteau (269 out of 426 patents)

silverMedal Graeme Jones (7 out of 7 patents)

bronzeMedal Jaro I Karppinen (4 out of 4 patents)

4.  Eric K H Dinkla (2 out of 2 patents)

5.  Herriot Tabuteu (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Antecip Bioventures Ii LLC. Retrieved from https://idiyas.com/company/antecip-bioventures-ii

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…